CINECA IRIS Institutional Research Information System

BERTOTTI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.061
AS - Asia 12.657
EU - Europa 10.789
SA - Sud America 771
OC - Oceania 298
AF - Africa 144
Continente sconosciuto - Info sul continente non disponibili 13
Totale 39.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.545
CN - Cina 6.590
IT - Italia 3.129
SG - Singapore 1.892
DE - Germania 1.396
GB - Regno Unito 1.395
JP - Giappone 1.174
FR - Francia 802
BR - Brasile 599
HK - Hong Kong 587
IN - India 581
ES - Italia 565
SE - Svezia 480
FI - Finlandia 463
KR - Corea 458
IE - Irlanda 418
NL - Olanda 403
CA - Canada 402
VN - Vietnam 266
TW - Taiwan 240
AU - Australia 227
PL - Polonia 219
CH - Svizzera 216
AT - Austria 205
BE - Belgio 191
TR - Turchia 190
UA - Ucraina 146
RU - Federazione Russa 125
ID - Indonesia 115
IL - Israele 102
GR - Grecia 95
PT - Portogallo 93
MX - Messico 89
TH - Thailandia 78
CZ - Repubblica Ceca 71
DK - Danimarca 71
NZ - Nuova Zelanda 69
RO - Romania 64
AR - Argentina 62
IR - Iran 57
NO - Norvegia 56
SA - Arabia Saudita 42
ZA - Sudafrica 41
MY - Malesia 40
PK - Pakistan 37
HU - Ungheria 36
CO - Colombia 31
BD - Bangladesh 30
EG - Egitto 26
CL - Cile 25
EC - Ecuador 23
EE - Estonia 21
JO - Giordania 21
LT - Lituania 20
IQ - Iraq 19
HR - Croazia 17
AM - Armenia 14
LB - Libano 14
NG - Nigeria 13
PE - Perù 13
PH - Filippine 13
SK - Slovacchia (Repubblica Slovacca) 13
UZ - Uzbekistan 13
KE - Kenya 12
SI - Slovenia 12
MO - Macao, regione amministrativa speciale della Cina 11
RS - Serbia 11
SN - Senegal 11
TN - Tunisia 11
BG - Bulgaria 10
KZ - Kazakistan 10
QA - Qatar 10
BA - Bosnia-Erzegovina 9
MA - Marocco 8
NP - Nepal 8
AE - Emirati Arabi Uniti 7
LU - Lussemburgo 7
UY - Uruguay 7
AP - ???statistics.table.value.countryCode.AP??? 6
BY - Bielorussia 6
LK - Sri Lanka 6
OM - Oman 6
CY - Cipro 5
EU - Europa 5
GE - Georgia 5
IS - Islanda 5
SY - Repubblica araba siriana 5
VE - Venezuela 5
CI - Costa d'Avorio 4
CU - Cuba 4
DZ - Algeria 4
PA - Panama 4
AL - Albania 3
BO - Bolivia 3
IM - Isola di Man 3
KH - Cambogia 3
MD - Moldavia 3
MK - Macedonia 3
MQ - Martinica 3
MT - Malta 3
Totale 39.686
Salva come PNG Salva come JPEG
Città #
Beijing 1.189
Singapore 1.128
Ann Arbor 1.068
Shanghai 913
Chandler 826
Ashburn 825
Fairfield 798
Houston 628
Redwood City 487
Guangzhou 473
Seattle 454
Cambridge 441
Woodbridge 408
Dublin 381
Tokyo 373
Turin 372
Wilmington 356
Santa Clara 351
Torino 339
Milan 313
Nanjing 267
New York 261
Munich 251
Los Angeles 239
Hangzhou 193
Dallas 166
Dearborn 160
The Dalles 159
Lappeenranta 157
Boston 152
Wuhan 152
Hong Kong 149
Seoul 149
London 148
Pisa 148
San Diego 145
Vienna 145
Taipei 144
Nyköping 142
Columbus 134
Boardman 128
Rome 126
Helsinki 123
Paris 123
Warsaw 122
Hefei 118
Chengdu 116
Amsterdam 114
Jacksonville 114
Barcelona 109
Naples 109
Zhengzhou 108
Chicago 107
Villeurbanne 106
Medford 99
Princeton 99
Toronto 97
San Francisco 92
Changsha 89
Jakarta 87
São Paulo 87
Madrid 83
Fremont 82
Duncan 81
Central 80
Tianjin 79
Buffalo 75
Berlin 74
Shenyang 74
Manchester 71
Bengaluru 70
Ottawa 70
Jinan 69
Brussels 68
San Jose 67
Chongqing 65
Central District 64
Mumbai 60
Dong Ket 58
Ho Chi Minh City 56
Istanbul 55
Frankfurt am Main 54
Nanchang 54
Phoenix 54
Shenzhen 51
Philadelphia 50
Sydney 50
Genoa 49
Nuremberg 46
Heidelberg 45
Fuzhou 43
Atlanta 42
Hanoi 42
Xian 42
Carrara 41
Melbourne 41
Moscow 41
Nashville 41
Silver Spring 40
Toulouse 39
Totale 20.123
Salva come PNG Salva come JPEG
Nome #
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. 6.398
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.880
Adaptive mutability of colorectal cancers in response to targeted therapies 2.339
Stromal contribution to the colorectal cancer transcriptome. 2.051
MET signalling: principles and functions in development, organ regeneration and cancer. 1.855
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.262
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 893
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 870
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 846
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 773
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 665
MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. 447
The genomic landscape of response to EGFR blockade in colorectal cancer 423
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 390
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer 387
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 384
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 367
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 335
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts 333
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 324
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype 317
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 305
Only a subset of Met-activated pathways are required to sustain oncogene addiction 298
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 296
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 293
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 292
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 274
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 274
Inhibition of Src impairs the growth of met-addicted gastric tumors. 269
Met-driven invasive growth involves transcriptional regulation of Arhgap12 266
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 265
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 262
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 259
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 249
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 245
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 243
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 233
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 222
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors 216
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 203
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS. 202
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 200
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells 200
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga 194
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 188
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 188
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 184
Effective drug combinations in breast, colon and pancreatic cancer cells 183
Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma 182
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 181
Semalytics: a semantic analytics platform for the exploration of distributed and heterogeneous cancer data in translational research 181
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer 180
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer 178
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 177
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 176
PDX-MI: Minimal information for patient-derived tumor xenograft models 174
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 160
One tool to find them all: A case of data integration and querying in a distributed LIMS platform 160
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 148
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 143
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin 140
CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system 140
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases 140
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 132
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 131
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 127
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 121
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models 121
Met as a potential therapeutic target in basal-like breast cancer 117
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. 116
LAS: A Bio-Clinical Integrated Laboratory Information System for Translational Data Management 116
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 114
Animal research: Temper Italy's strict lab-animal law. 109
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways 109
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer 108
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) 107
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. 106
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients 104
Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity 103
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 95
Tyrosine kinase signal specificity: lessons from the HGF receptor. 95
The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization 94
Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity 92
DNA demethylation triggers cell free DNA release in colorectal cancer cells 92
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer 91
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma 90
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells 89
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation 84
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling 80
EGAsubmitter: A software to automate submission of nucleic acid sequencing data to the European Genome-phenome Archive 79
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 74
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer 73
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer 71
Interrogating open issues in cancer precision medicine with patient-derived xenografts 69
Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies 67
MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis 66
Abstract 2613: A modified Luria-Delbrück assay allows quantification of colorectal cancer persister cells’ mutation rate 65
Genome-wide CRISPR screens reveal Hippo pathway activation as a resistance mechanism in BRAF mutant colon cancer 65
Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer 63
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts 59
Totale 39.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.723
article - articoli 0
book - libri 0
conference - conferenze 5.778
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.241 0 0 0 0 0 487 547 325 463 460 423 536
2021/20225.203 495 490 466 507 385 390 448 404 405 284 523 406
2022/20234.222 328 340 245 405 325 590 310 397 440 219 306 317
2023/20244.918 381 405 312 432 359 399 407 415 154 534 645 475
2024/20257.059 373 443 501 602 960 595 462 601 754 535 553 680
2025/20264.124 942 543 567 890 1.035 147 0 0 0 0 0 0
Totale 40.342